

Patients' and consumers' organisation funding sources

NAME OF ORGANISATION: Myeloma Patients Europe (MPE)

YEAR: 2020

MPE Industry ¹ related income ²		
Name of company/ funder	Amount of income	% of overall organisation's income
AMGEN	103.308 €	10,2 %
ASTRA ZENECA	10.000 €	1,0 %
BRISTOL-MYERS SQUIBB	221.226 €	21,8 %
CELGENE	525 €	0,1 %
JANSSEN	93.268 €	9,2 %

¹ Industry is defined as commercial manufacturers of healthcare products and services, including distributors and wholesalers, etc.

² This should reflect the overall funding received from industry, including, e.g. projects, conferences, etc.


KARYOPHARM	55.000 €	5,4 %
MUNDIBIOPHARMA	7.000 €	0,7 %
NOVARTIS	65.000 €	6,4 %
ONCOPEPTIDES	15.000 €	1,5 %
PFIZER	65.000 €	6,4 %
ROCHE	53.000 €	5,2 %
SANOFI	65.380 €	6,4 %
TAKEDA	97.220 €	9,6 %
Subtotal:	991.927 €	97,7 %

MPE Non-industry related income – Public Funding		
Source of funding³	Amount of income	% of overall organisation's income
IMI HARMONY	5.557 €	0,5 %
Subtotal:	5.557 €	0,5 %

MPE Non-industry related income		
DONATION	5.000 €	0,5 %
REFUND- Tryp Hotel Madrid	9.581 €	0,9 %
REFUND - Non Industry (various)	2.165 €	0,2 %
REFUND - Social security contribution	1.069 €	0,1 %
Subtotal:	17.816 €	1,8 %
TOTAL⁴:	1.015.299 €	100 %

³ E.g. membership fees, donations.

⁴ In case the total figures in this table do not match those in the financial statement, please provide justification (attached here or as an email).



Information required to be included on organisation's website	Please include links below:
<ul style="list-style-type: none">Funding sources:	https://www.mpeurope.org/about-mpe/funding-sources/
<ul style="list-style-type: none">Overall proportion of industry and non-industry:	Industry: 97,7 %; Non-Industry: 2,3 %.
<ul style="list-style-type: none">Percentage of the highest contribution from a single company:	21,8 % of overall organizations income

Comments/explanatory notes:

When completing the form you may refer to the guidance document here (in particular point 4, pages 8-9):

http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2015/05/WC500187018.pdf